Clinical trials: Obesity Associated Disorder
Proteinuric Kidney Disease, Diabetic Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months).
- Conditions
- Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy
- Trial name
- NCT01129557
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Non-Alcoholic Fatty Liver Disease, Obesity
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat
- Trial name
- NCT03375788
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Obesity, Morbid, Insulin Resistance
Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients
More and more people in Canada and around the world are severely (morbidly) obese, and this is associated with a high risk for poor blood sugar control (insulin resistance, IR) and diabetes.
- Trial name
- NCT02970877
- Testing
- Fecal filtrate from 150 g stool from healthy lean donors, Fecal filtrate from 150 g of the recipient's own stool
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Johane Allard
Obesity Associated With Defects in Leptin-melanocortin Pathway
Long Term Extension Trial of Setmelanotide
This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated…
- Trial name
- NCT03651765
- Testing
- Setmelanotide
- Where
- 27 sites in United States, Canada and 6 more
- Volunteers
- 205 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Diabetes Mellitus
Adjunctive Metformin Therapy in Double Diabetes
The significance of this project is to investigate the effects of adjunctive metformin therapy in children and adolescents with double diabetes.
- Trial name
- AMTIDD (NCT01334125)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Massachusetts, Worcester
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Weight Gain
Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
The purpose of this research study is to test the safety and efficacy (how well it works) of exenatide as a treatment for weight gain associated with olanzapine in obese adults with Bipolar Disorder, Major Depressive Disorder…
- Trial name
- NCT00845507
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Cincinnati
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
Atherogenic Dyslipidemia, Obesity Associated Disorder
Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
Atherogenic Dyslipidemia (AD) is a risk-conferring lipid/lipoprotein profile that comprises a higher proportion of small LDL particles, reduced HDL-C, and increased triglycerides.
- Trial name
- NCT03615534
- Testing
- Therapeutic Lifestyle Changes, Fenofibrate, Wax Matrix Extended Release Niacin (WMER Niacin)
- Where
- 2 sites in Iraq
- Volunteers
- 161 people
- Sponsor
- Lewai Sharki Abdulaziz, MSc PhD
Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome
Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT07566299
- Volunteers
- 118,805 people
- Sponsor
- Chung Shan Medical University
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
This program aims to help Veterans who take antipsychotic medications lose weight. We use a program based on the American Diabetes Association's "Diabetes Prevention Program," and we have modified it to fit the lifestyles of…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO2 (NCT01052714)
- Testing
- Lifestyle Balance
- Where
- 3 sites in United States
- Volunteers
- 121 people
- Sponsor
- VA Office of Research and Development
HIV/AIDS, Lipohypertrophy
Effects of Semaglutide in HIV-Associated Lipohypertrophy
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream…
- Conditions
- HIV/AIDS, Lipohypertrophy, Obesity
- Trial name
- NCT04019197
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Obesity
Daily Self-weighing and Holiday-associated Weight Gain in Adults
Background: Previous studies report 0.4-1.5kg of weight gain during the holiday season, which may contribute to annual weight gain. Purpose: To test whether daily self-weighing (DSW) can prevent holiday weight gain.
- Trial name
- NCT03718000
- Testing
- Daily self-weighing (DSW)
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Obesity
Dexmedetomidine to Treat Bariatric Surgery-associated Pain
Obesity represents one of the most important public health issues according to the World Health Organization and it has reached epidemic proportions globally.
- Trial name
- NCT02880540
- Testing
- Fentanyl, Morphine, Dexmedetomidine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Janelle Vaughns
Bariatric Surgery Candidate, Bone Loss
Weight Loss With Risedronate for Bone Health
This is a pilot project to determine the feasibility of recruiting, enrolling, treating, and following 24 older sleeve gastrectomy patients into a randomized controlled trial (RCT) examining the efficacy of bisphosphonate use…
- Conditions
- Bariatric Surgery Candidate, Bone Loss, Weight Loss
- Trial name
- WERISE (NCT03411902)
- Testing
- Risedronate Sodium 150 MG
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
Obesity
Effect of Fibre Products on Appetite and Weight
This study explores the nutritional effects of fibre. Short chain fatty acid(SCFA), such as propionate, are produced through the fermentation of fibre in the bowel.
- Trial name
- NCT00750438
- Testing
- Propionate ester, Inulin, Cellulose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
This program aims to help Veterans who take antipsychotic medications lose weight. The investigators use a program based on the American Diabetes Association's "Diabetes Prevention Program," and the investigators have modified it…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO (NCT00344500)
- Testing
- Behavioral Weight Loss Program
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development